While U.S. industry leaders continued to complain about slow FDA device reviews and have been swayed to move a growing share of product development overseas, there’s been a little-...
“In the 2000s, venture capital investments in healthcare and life sciences outperformed venture investments in tech.” Device company executives could be forgiven for not having...